Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 6/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.38 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24342160 | 0.93 | OPRL1 (0.40) | OPRL1ACEACE2HRH1OPRD1 | |
| SCHEMBL24342121 | 0.93 | OPRL1 (0.41) | OPRL1HRH1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL24342159 | 0.93 | OPRL1 (0.41) | OPRL1HRH1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL26458009 | 0.90 | OPRL1 (0.39) | OPRL1ACEACE2OPRK1ALDH1A1 | |
| SCHEMBL24342162 | 0.90 | OPRL1 (0.39) | OPRL1ACEACE2OPRD1OPRK1 | |
| SCHEMBL25764635 | 0.87 | OPRL1 (0.42) | OPRL1ACEACE2OPRD1ALDH1A1 | |
| SCHEMBL25881766 | 0.87 | OPRL1 (0.42) | OPRL1ACEACE2OPRD1ALDH1A1 | |
| SCHEMBL27268254 | 0.86 | OPRL1 (0.43) | OPRL1OPRD1OPRK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL23680330 | 0.85 | OPRL1 (0.40) | OPRL1HRH1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL21916127 | 0.85 | OPRL1 (0.40) | OPRL1HRH1OPRD1OPRK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2023-05-04 | — | — | US | disclosed |
| WO-2020244657-A1 | ANTI-B7-H4 ANTIBODY–DRUG CONJUGATE AND MEDICINAL USE THEREOF | 上海翰森生物医药科技有限公司 | 2020-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230140397-A1 | ANTI-PSMA ANTIBODY-EXATECAN ANALOGUE CONJUGATE AND MEDICAL USE THEREOF | FOLH1, ENPEP, PEPD | OPRL1 1346/4885ACE 948/4885ACE2 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.